Journal Mobile Options
Table of Contents
Vol. 71, No. 3, 2004
Issue release date: April 2004
Pathobiology 2004;71:137–143
(DOI:10.1159/000076468)

Frequent Loss of RUNX3 Expression by Promoter Hypermethylation in Gastric Carcinoma

Oshimo Y. · Oue N. · Mitani Y. · Nakayama H. · Kitadai Y. · Yoshida K. · Ito Y. · Chayama K. · Yasui W.
Departments of aMolecular Pathology, bMedicine and Molecular Science, Hiroshima University Graduate School of Biomedical Sciences, and cSurgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; dInstitute of Molecular and Cell Biology, National University of Singapore, Singapore, Singapore

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

The RUNX3 gene is a member of the Runt domain family of transcription factors that are master regulators of gene expression in major developmental pathways. Recently, lack of RUNX3 function was found to be associated with genesis and progression of gastric carcinoma. We studied methylation of CpG islands in the RUNX3 gene by methylation-specific PCR in 80 gastric carcinoma specimens, 45 corresponding non-neoplastic mucosae, and 7 gastric carcinoma cell lines. We also measured levels of RUNX3 mRNA in 50 of the gastric carcinoma cases by quantitative RT-PCR and in the gastric carcinoma cell lines by RT-PCR. Hypermethylation of the RUNX3 promoter was found in 57 (71%) of 80 gastric carcinomas, and promoter hypermethylation of RUNX3 occurred more frequently in intestinal and diffuse-adherent type tumors than in diffuse-scattered type tumors (p = 0.046). Reduced RUNX3 expression was associated with promoter hypermethylation (p = 0. 036), however, there was no correlation between RUNX3 mRNA expression levels and T grade, N grade, tumor stage, or histological type. In corresponding non-neoplastic mucosae, hypermethylation of the RUNX3 promoter was found in 38 (84%) of 45 specimens. Among seven gastric carcinoma cell lines, three cell lines (MKN-28, MKN-74, TMK-1) with diminished expression of RUNX3 had promoter methylation and three cell lines (MKN-1, MKN-7, MKN-45) with RUNX3 expression showed no promoter methylation. Our results overall suggest that transcriptional inactivation of RUNX3 by promoter hypermethylation may participate in the stomach carcinogenesis.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Yasui W, Yokozaki H, Fujimoto J, Naka K, Kuniyasu H, Tahara E: Genetic and epigenetic alterations in multistep carcinogenesis of the stomach. J Gastroenterol 2000;35:111–115.
  2. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE: E-cadherin germline mutations in familial gastric cancer. Nature 1998;392:402–405.
  3. Kim JH, Takahashi T, Chiba I, Park JG, Birrer MJ, Roh JK, De Lee H, Kim JP, Minna JD, Gazdar AF: Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines. J Natl Cancer Inst 1991;83:938–943.
  4. Park K, Kim SJ, Bang YJ, Park JG, Kim NK, Roberts AB, Sporn MB: Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: Correlation with sensitivity to growth inhibition by TGF-beta. Proc Natl Acad Sci USA 1994;91:8772–8776.
  5. Fleisher AS, Esteller M, Wang S, Tamura G, Suzuki H, Yin J, Zou TT, Abraham JM, Kong D, Smolinski KN, Shi YQ, Rhyu MG, Powell SM, James SP, Wilson KT, Herman JG, Meltzer SJ: Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 1999;59:1090–1095.
  6. Leung SY, Yuen ST, Chung LP, Chu KM, Chan AS, Ho JC: hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res 1999;59:159–164.
  7. Shim YH, Kang GH, Ro JY: Correlation of p16 hypermethylation with p16 protein loss in sporadic gastric carcinomas. Lab Invest 2000;80:689–695.
  8. Tamura G, Yin J, Wang S, Fleisher AS, Zou T, Abraham JM, Kong D, Smolinski KN, Wilson KT, James SP, Silverberg SG, Nishizuka S, Terashima M, Motoyama T, Meltzer SJ: E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 2000;92:569–573.
  9. Oue N, Shigeishi H, Kuniyasu H, Yokozaki H, Kuraoka K, Ito R, Yasui, W: Promoter hypermethylation of MGMT is associated with protein loss in gastric carcinoma. Int J Cancer 2001;93:805–809.
  10. Hayashi K, Yokozaki H, Goodison S, Oue N, Suzuki T, Lotan R, Yasui W, Tahara E: Inactivation of retinoic acid receptor beta by promoter CpG hypermethylation in gastric cancer. Differentiation 2001;68:13–21.
  11. Byun DS, Lee MG, Chae KS, Ryu BG, Chi SG: Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res 2001;61:7034–7038.
  12. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC, Ito Y: Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002;109:113–124.

    External Resources

  13. Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, Guo WH, Imamura T, Ishidou Y, Fukuchi M, Shi MJ, Stavnezer J, Kawabata M, Miyazono K, Ito Y: Interaction and functional cooperation of PEBP2/CBF with Smads: Synergistic induction of the immunoglobulin germline C alpha promoter. J Biol Chem 1999;274:31577–31582.
  14. Lauren P: The two histological main types of gastric carcinoma. Diffuse and so-called intestinal type carcinoma: An attempt at histological classification. Acta Pathol Microbiol Scand 1965;64:31–49.
  15. Shimoyama Y, Hirohashi S: Expression of E- and P-cadherin in gastric carcinomas. Cancer Res 1991;51:2185–2192.
  16. Sobin LH, Wittekind CH (eds): TNM Classification of Malignant Tumors, ed 5. New York, Wiley-Liss, 1997, pp 59–62.
  17. Ochiai A, Yasui W, Tahara E: Growth-promoting effect of gastrin on human gastric carcinoma cell line TMK-1. Jpn J Cancer Res 1995;76:1064–1071.
  18. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821–9826.
  19. Esteller M, Corn PG, Baylin SB, Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225–3229.
  20. Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, Baylin SB, Issa JP: Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999;59:5438–5442.
  21. Tsuchiya T, Tamura G, Sato K, Endoh Y, Sakata K, Jin Z, Motoyama T, Usuba O, Kimura W, Nishizuka S, Wilson KT, James SP, Yin J, Fleisher AS, Zou T, Silverberg SG, Kong D, Meltzer SJ: Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia. Oncogene 2000;19:3642–3646.
  22. Sato K, Tamura G, Tsuchiya T, Endoh Y, Usuba O, Motoyama T: Frequent loss of expression without sequence mutations of the DCC gene in primary gastric cancer. Br J Caner 2001;85:199–203.
  23. Riggins AB, Kinzler KW, Vogelstein B, Thiagalingam S: Frequency of Smad gene mutations in human cancers. Cancer Res 1997;57:2578–2580.
  24. Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, Tsui LC, Bapat B, Gallinger S, Andrulis IL, Thomsen GH, Wrana L, Attisano L: MADR2 maps to 18q21 and encodes a TGF-beta-regulated MAD-related protein that is mutated in colorectal carcinoma. Cell 1996;86:543–552.
  25. Makkowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M, Willson JKV: Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336–1338.
  26. Nishizuka S, Tamura G, Maesawa C, Sakata K, Suzuki Y, Iwaya T, Terashima M, Saito K, Satodate R: Analysis of the DPC4 gene in gastric carcinoma. Jpn J Cancer Res 1997;88:335–339.
  27. Shitara Y, Yokozaki H, Yasui W, Takenoshita S, Kuwano H, Nagamachi Y, Tahara E: No mutations of Smad2 gene in human sporadic gastric carcinomas. Jpn J Clin Oncol 1999;29:3–7.
  28. Shitara Y, Yokozaki H, Yasui W, Takenoshita S, Nagamachi Y, Tahara E: Mutation of the transforming growth factor-beta type II receptor gene is a rare event in human sporadic gastric carcinomas. Int J Oncol 1998;12:1061–1065.
  29. Renault B, Calistri D, Buonsanti G, Nanni O, Amadori D, Ranzani GN: Microsatellite instability and mutations of p53 and TGF-beta RII genes in gastric cancer. Hum Genet 1996;98:601–607.
  30. Oue N, Sentani K, Yokozaki H, Kitadai Y, Ito R, Yasui W: Promoter methylation status of the DNA repair genes hMLH1 and MGMT in gastric carcinoma and metaplastic mucosa. Pathobiology 2001;69:143–149.
  31. Kang GH, Shim YH, Jung HY, Kim WH, Ro JY, Rhyu MG: CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res 2001;61:2847–2851.
  32. To KF, Leung WK, Lee TL, Yu J, Tong JH, Chan MW, Ng EK, Chung SC, Sung JJ: Promoter hypermethylation of tumor-related genes in gastric intestinal metaplasia of patients with and without gastric cancer. Int J Cancer 2002;102:623–628.
  33. Waki T, Tamura G, Tsuchiya T, Sato K, Nishizuka S, Motoyama T: Promoter methylation status of E-cadherin, hMLH1, and p16 genes in nonneoplastic gastric epithelia. Am J Pathol 2002;161:399–403.

    External Resources

  34. Baylin SB, Herman J G, Graff JR, Vertino PM, Issa JP: Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141–196.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50